Avi Veidman is co-founder and CEO of Nucleai, a spatial biology platform company transforming drug R&D and clinical treatment decisions powered by AI Pathology. The platform is used for translational and exploratory research in pharma companies. He was a key player in fundraising for the company (Three investment rounds summing up to $50 million from world-leading Tech-Bio investors - Section32 and Sanofi). Previously, he held technology leadership roles in elite technological units in the Israeli intelligence force and established an AI-Data science department specializing in computer vision and spatial information analysis. Avi holds an MSc and BSc in Geoinformatics (Cum Laude) from the Technion.